Efficacy and Safety of Rituximab in Moderately-to-Severely Active Systemic Lupus Erythematosus: The Randomized, Double-Blind, Phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab Trial

OBJECTIVE: B cells are likely to contribute to the pathogenesis of systemic lupus erythematosus (SLE), and rituximab induces depletion of B cells. The Exploratory Phase II/III SLE Evaluation of Rituximab (EXPLORER) trial tested the efficacy and safety of rituximab versus placebo in patients with mod...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Arthritis Rheum
Autores principales: Merrill, Joan T., Neuwelt, C. Michael, Wallace, Daniel J., Shanahan, Joseph C., Latinis, Kevin M., Oates, James C., Utset, Tammy O., Gordon, Caroline, Isenberg, David A., Hsieh, Hsin-Ju, Zhang, David, Brunetta, Paul G.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2010
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4548300/
https://ncbi.nlm.nih.gov/pubmed/20039413
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.27233
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares